FILE:DGX/DGX-8K-20070530190734.txt.gz
EVENTS:	Entry into a Material Definitive Agreement	Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant	Other Events	Financial Statements and Exhibits
TEXT:
ITEM: Entry into a Material Definitive Agreement
ITEM: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM: Other Events
ITEM: Financial Statements and Exhibits
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Item 1.01. Entry into a Material Definitive Agreement
          
On May 25, 2007, Quest Diagnostics Receivables Inc. (the "Company"), as Borrower, a wholly-owned subsidiary of Quest Diagnostics Incorporated ("Parent"), as initial servicer, Variable Funding Capital Company LLC and Wachovia Bank, National Associates (collectively, the "VFCC Group"), Atlantic Asset Securitization LLC and Calyon New York Branch (collectively, the "Atlantic Group"), Wachovia Bank, National Association and Calyon New York Branch (collectively, the "Atlantic Agent"), and Wachovia Bank, National Association, as Administrative Agent, entered into an amendment of the Third Amended and Restated Credit and Security Agreement. The amendment increased the receivables securitization facility (the "Secured Receivables Credit Facility") from $300 million to $375 million. The amendment also extended the scheduled termination date of the Secured Receivables Credit Facility from July 31, 2007 to May 23, 2008. Interest on the Secured Receivables Credit Facility is based on rates that are intended to approximate commercial paper rates for highly rated issuers. The Secured Receivables Credit Facility is supported by one-year back-up facilities provided by two banks on a committed basis.
          
A copy of the amendment is attached as Exhibit 10.1.
Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
          
The information contained in Item 1.01 is incorporated herein by reference. As of May 25, 2007, $300 million was outstanding under the Secured Receivables Credit Facility.
Item 8.01 Other Events.
          
The Company announced in a press release dated May 30, 2007, which is attached as exhibit 99.1 hereto and incorporated herein by reference, that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act expired on Tuesday, May 22, 2007 with respect to the Company's agreement to acquire AmeriPath, Inc.
Item 9.01. Financial Statements and Exhibits
          
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

E
XHIBIT
10.1
                    
THIS AMENDMENT NO. 5 TO THIRD AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT
(this
"Amendment"
) is entered into as of May 25, 2007, by and among:
with respect to that certain Third Amended and Restated Credit and Security Agreement dated as of April 20, 2004, by and among the parties hereto (as heretofore amended, the
"Existing Agreement"
which, as amended hereby, is hereinafter referred to as the
"Agreement"
).
                    
Unless otherwise indicated, capitalized terms used in this Amendment are used with the meanings attributed thereto in the Existing Agreement.
 
                    
WHEREAS,
the parties hereto desire to extend the Scheduled Termination Date; and
                    
WHEREAS,
the parties hereto desire to amend the Existing Agreement as hereinafter set forth.
                    
NOW, THEREFORE,
in consideration of the premises and the mutual agreements herein contained, the parties hereto hereby agree as follows:
                    
1.      
Amendments to Existing Agreement
.
Subject to the terms and conditions hereinafter set forth, the parties hereby agree to amend the Existing Agreement as follows:
                    
1.1      Section 1.7 of the Existing Agreement is hereby amended and restated in its entirety to read as follows:
                     
1.2      The initial Commitments of Wachovia Bank, National Association, and of Calyon New York Branch under the Existing Agreement are hereby changed to "$225,000,000" and "$150,000,000," respectively.
          
          1.3      The definition of
"Dilution"
in the Existing Agreement is hereby amended and restated in its entirety to read as follows:
                    
"Dilution"
means, total Net Revenues multiplied by the three month average calculated quarterly of (i)(a) for Originators on the QBS an amount equal to the dollar amount of adjustments measured by QBS adjustment codes 66, 70, 71, 72, 74, 75, 76, 83, 85 for client and patient Receivables, plus (b) an amount equal to 0.30 times the dollar amount of adjustments measured by the QBS adjustment codes 66, 70, 71, 72, 74, 75, 76, 83, 85 for third party Receivables, plus (c) 0.70 multiplied by the dollar amount of adjustments measured by QBS
adjustment code 68 for client and patient Receivables, excluding transfers between client and patient billing categories, divided by (ii) the Net Revenues generated by Originators on QBS.
                    
1.4      The definition of
"Eligible Receivable"
in the Existing Agreement is hereby amended to delete the following sentence at the end thereof:
 
                    
1.5      The definition of
"Scheduled Termination Date"
in the Existing Agreement is hereby amended and restated in its entirety to read as follows:
                    
1.6      The definition of
"Specified Government Ineligibles"
in the Existing Agreement is hereby amended and restated in its entirety to read as follows:
                    
1.7      Schedule 6.1(o) of the Existing Agreement is hereby amended and restated in its entirety to read as set forth in Annex A hereto.
                    
2.     
Representations
.
                    
2.1.      Each of the Loan Parties represents and warrants to the Lenders and the Agents that it has duly authorized, executed and delivered this Amendment and that the Agreement constitutes, a legal, valid and binding obligation of such Loan Party, enforceable in accordance with its terms (except as enforceability may be limited by applicable bankruptcy, insolvency, or similar laws affecting the enforcement of creditors' rights generally or by equitable principles relating to enforceability).
                    
2.2.      Each of the Loan Parties further represents and warrants to the Lenders and the Agents that each of its representations and warranties set forth in Section 6.1 of the Agreement is true and correct as of the date hereof and that no Event of Default or Unmatured Default exists as of the date hereof and is continuing.
                    
3.     
Conditions Precedent
.
This Amendment shall become effective as of the date first above written upon (a) receipt by the Administrative Agent of a counterpart hereof duly executed by each of the parties hereto, (b) receipt by the VFCC Agent of a counterpart of an amended and restated VFCC Fee Letter, duly executed by each of the parties thereto, together with payment of the Amendment Fee and Extension Fee (each, under and as defined therein), and (c) receipt by the Atlantic Agent of a counterpart of a second amended and restated Atlantic Fee letter, duly executed by each of the parties thereto, together with payment of the Amendment Fee and Extension Fee (each, under and as defined therein).
                    
4.     
Miscellaneous
.
                    
4.1.      Except as expressly amended hereby, the Existing Agreement shall remain unaltered and in full force and effect, and each of the parties hereby ratifies and confirms the Agreement and each of the other Transaction Documents to which it is a party.
                    
4.2.      THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK WITHOUT REFERENCE TO PRINCIPLES OF CONFLICTS OF LAW.
                    
4.3.      EACH LOAN PARTY HEREBY ACKNOWLEDGES AND AGREES THAT:
                    
4.3.1. IT IRREVOCABLY (i) SUBMITS TO THE NON-EXCLUSIVE JURISDICTION, FIRST, OF ANY UNITED STATES FEDERAL COURT, AND SECOND, IF FEDERAL JURISDICTION IS NOT AVAILABLE, OF ANY NEW YORK STATE COURT, IN EITHER CASE SITTING IN NEW YORK COUNTY, NEW YORK, IN ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THE AGREEMENT, AND (ii) WAIVES, TO THE FULLEST EXTENT IT MAY EFFECTIVELY DO SO, THE DEFENSE OF AN INCONVENIENT FORUM TO THE MAINTENANCE OF AN ACTION OR PROCEEDING IN SUCH COURTS.
                    
4.3.2. TO THE EXTENT THAT IT HAS OR HEREAFTER MAY ACQUIRE ANY IMMUNITY FROM THE JURISDICTION OF ANY COURT OR FROM ANY LEGAL PROCESS (WHETHER THROUGH SERVICE OR NOTICE, ATTACHMENT PRIOR TO JUDGMENT, ATTACHMENT IN AID TO EXECUTION, EXECUTION OR OTHERWISE) WITH RESPECT TO ITSELF OR ITS PROPERTY, IT HEREBY IRREVOCABLY WAIVES SUCH IMMUNITY IN RESPECT OF ITS OBLIGATIONS UNDER OR IN CONNECTION WITH THE AGREEMENT.
                    
4.4.      This Amendment may be executed in any number of counterparts and by the different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which when taken together shall constitute one and the same Amendment.
                    
IN WITNESS WHEREOF,
the parties hereto have executed this Amendment as of the date first above written.

Exhibit 99.1
LYNDHURST, N.J., May 30 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX ), the leading provider of diagnostic testing, information and services, announced today that it plans to complete its previously announced acquisition of AmeriPath, Inc. on May 31, 2007. The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act expired on May 29, 2007.
About AmeriPath
AmeriPath, a leading national provider of physician-based anatomic pathology, dermatopathology and molecular diagnostic services to physicians, hospitals, clinical laboratories and surgery centers, supports community-based medicine by helping physicians provide excellent and effective care for their patients. A team of sub-specialized pathologists and Ph.D. scientists provide medical expertise, diagnostic quality, and personal consultation services. AmeriPath's team of approximately 400 highly trained, board-certified pathologists provide medical diagnostics services in outpatient laboratories owned, operated and managed by AmeriPath, as well as in hospitals and ambulatory surgical centers.
About Quest Diagnostics
Quest Diagnostics is the leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its national network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative new diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at:
www.questdiagnostics.com
<http://www.questdiagnostics.com>
.
This communication contains certain forward-looking statements. These forward-looking statements, which may include, but are not limited to, statements concerning the proposed acquisition, are based on management's current expectations and estimates and involve risks and uncertainties that could cause actual results or outcomes to differ materially from those contemplated by the forward-looking statements. Certain of these risks and uncertainties may include, but are not limited to the risks and uncertainties described in the Quest Diagnostics Incorporated 2006 Form 10-K and subsequent filings.
Source: Quest Diagnostics Incorporated


